Observational studyNeurology(R) neuroimmunology & neuroinflammation2019

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Tjalf Ziemssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.